HAVCR2 and acute myeloid leukemia: Further, antibodies targeting immune checkpoints such as TIGIT, PD-1, and TIM-3 have theoretical potential, as blocking these checkpoints with specific antibodies helps in reversing the diminished NK cytolytic activity in AML patients.